BioCryst Pharmaceuticals BCRX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's accounts receivable?
- BioCryst Pharmaceuticals (BCRX) reported accounts receivable of $109.27M in Q1 2026.
- How has BioCryst Pharmaceuticals's accounts receivable changed year-over-year?
- BioCryst Pharmaceuticals's accounts receivable increased by 17.0% year-over-year, from $93.39M to $109.27M.
- What is the long-term trend for BioCryst Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's accounts receivable has grown at a 65.3% compound annual growth rate (CAGR), from $8.65M to $106.82M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.